USA – Aptar Pharma, a global leader in drug delivery systems, services, and active material science solutions, has formed an exclusive partnership with Stallergenes Greer, a global healthcare company specializing in allergen immunotherapy (AIT), to create the first-of-its-kind connected drug delivery device.
The partnership will also see to the development of companion mobile app for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions.
Non-compliance with an AIT schedule and premature discontinuation of treatment continue to be issues in AIT management.
This innovative, user-friendly connected device will help to improve dose compliance and adherence, thereby optimizing patient treatment outcomes.
Patient support programs and the provision of digital tools that prioritize the patient are central to Aptar Pharma’s vision for the future of digital health, and they are a means of ensuring true patient centricity.
This collaboration highlights Aptar Pharma’s progress in the field of digital therapeutics, with development work being carried out by its Digital Health Group, which offers a full turnkey solution that includes device and software development expertise.
Sai Shankar, vice president, Global Digital Healthcare Systems, Aptar Pharma said: “We are pleased to combine Aptar Pharma’s Digital Health ecosystem with Stallergenes Greer’s knowledge and leading position in AIT to further improve the treatment journey of patients who suffer from allergies.”
Dominique Pezziardi, general manager France, Belgium & Luxembourg, global head of Pricing and Market Access, Stallergenes Greer added: “This exclusive partnership with Aptar Pharma demonstrates the intensification of Stallergenes Greer’s investments in innovation to provide a large range of precise personalized allergen immunotherapy options adapted to the individual needs and lifestyle of patients.
Stallergenes Greer is well advanced on its digital transformation journey and will continue to develop its e-health offering for the benefit of all stakeholders.
The newly developed connected device and mobile app, which are part of Aptar Pharma’s portfolio of digital healthcare solutions, are expected to be available in France in 2022 and will be gradually rolled out across Stallergenes Greer’s markets.